AHI welcomes animal health carveout in new pharma tariff order
Bottom line
Veterinary drug makers are getting at least a temporary reprieve from the Trump administration’s new pharmaceutical tariff regime. In an April 6 statement, the Animal Health Institute said it appreciated the April 2 presidential proclamation, “Adjusting Imports of Pharmaceuticals and Pharmaceutical Ingredients into the United States,” because it explicitly recognizes animal health products. AHI President and CEO Martha Scott Poindexter said the group is still reviewing the details, but plans to work with the administration on implementation and on increasing domestic investment and production of animal health products. The proclamation itself creates a pathway for animal health pharmaceuticals to receive a 0% tariff rate if the Commerce secretary determines they come from a jurisdiction with a current or forthcoming trade and security framework agreement, or if they meet an urgent U.S. health need. (ahi.org)
Why it matters: For veterinarians, livestock producers, and animal health manufacturers, the key issue is supply continuity. The broader proclamation imposes steep new tariffs on patented pharmaceuticals and associated ingredients under Section 232, with the administration framing import dependence as a national security risk. AHI’s response suggests the industry sees the animal health language as an important safeguard against higher costs or product disruptions, especially for medicines used in companion animal and food-animal care. Trade lawyers reviewing the proclamation have also noted that animal health products appear to fall within the specialty-product category eligible for zero tariffs, though implementation details and certification criteria are still unclear. (public-inspection.federalregister.gov)
What to watch: Watch for Commerce Department guidance on how animal health products will qualify for tariff relief, and whether manufacturers need product-by-product certifications before the first tariff deadlines later this summer. (cov.com)
The Animal Health Institute is signaling cautious relief after President Donald Trump’s April 2, 2026, proclamation on pharmaceutical tariffs carved out a potential exemption for animal health products. In a statement published April 6, AHI President and CEO Martha Scott Poindexter thanked the administration for recognizing the value of animal health products and said the group wants to work with federal officials on implementation while supporting more domestic investment and production. (ahi.org)
The backdrop is a much broader trade action. The White House proclamation, issued under Section 232 of the Trade Expansion Act, says imports of patented pharmaceuticals and associated active pharmaceutical ingredients threaten U.S. national security because of heavy reliance on overseas manufacturing. In the proclamation and the Federal Register version, the administration cited FDA data indicating that, as of 2025, about 53% of patented pharmaceutical products distributed domestically were produced outside the United States, and only 15% of patented APIs by volume for the U.S. market were produced domestically. The order directs the administration to pursue additional agreements and imposes a 100% ad valorem duty on covered patented pharmaceuticals and associated ingredients, unless another provision applies. (public-inspection.federalregister.gov)
What changed for animal health is the specialty-product language. The proclamation says certain categories, including orphan drugs, nuclear medicines, plasma-derived therapies, fertility treatments, cell and gene therapies, antibody-drug conjugates, medical countermeasures, and “pharmaceutical products for animal health,” can receive a 0% tariff rate if the Commerce secretary, in consultation with USTR and HHS, determines the products either come from a jurisdiction with a current or forthcoming trade and security framework agreement or meet an urgent U.S. health need. That conditional language matters: the exemption is not automatic, and the administration still has to define how products will be identified or certified. (whitehouse.gov)
AHI’s statement was notably measured. Poindexter said the organization is “still analyzing the Proclamation” but thanked the administration for acting to protect the ability of veterinarians, farmers, and ranchers to keep animals healthy. That framing suggests the industry is trying to balance two priorities at once: avoiding sudden cost shocks or shortages tied to tariffs, while aligning with the administration’s push for more U.S.-based manufacturing capacity. (ahi.org)
Outside analysts have interpreted the proclamation similarly. Covington said animal health pharmaceuticals may be added to the 0% specialty-product category, while warning that it remains unclear whether Commerce will issue guidance explaining what counts as an urgent U.S. health need. Other legal analyses have described animal health as one of the categories singled out for favorable treatment, even as the broader tariff framework remains aggressive and complex, with implementation beginning July 31, 2026, for certain larger companies and later for smaller ones. (cov.com)
Why it matters: For veterinary professionals, this is less about Washington trade policy in the abstract and more about whether essential medicines stay available and affordable. Many veterinary drugs, biologics, and ingredients move through global supply chains. If animal health products were swept fully into the tariff regime, clinics and producers could face higher acquisition costs, tighter inventories, or both. The proclamation’s animal health language reduces that immediate risk, but because the carveout depends on future Commerce determinations, uncertainty remains. Practices, distributors, and manufacturers may need to monitor sourcing, contract terms, and inventory planning closely in the months ahead. (whitehouse.gov)
There’s also a longer-term policy implication. AHI’s emphasis on domestic investment lines up with a broader industry conversation about resilience in animal health supply chains. If the administration uses tariff relief to encourage more U.S. production of veterinary pharmaceuticals and ingredients, that could eventually reshape manufacturing strategies. But building new capacity takes time, regulatory coordination, and capital, so any near-term benefit for veterinarians will depend on how flexibly the exemption process is administered. This is an inference based on the proclamation’s structure and AHI’s response, rather than an explicit government timeline. (ahi.org)
What to watch: The next key step is federal implementation. The proclamation directs the administration to continue negotiations and report progress within 90 days of April 2, 2026, and outside analyses indicate tariff deadlines for some covered pharmaceutical imports begin July 31, 2026. For the animal health sector, the practical question is whether Commerce issues clear guidance soon on eligibility, certification, and which veterinary products qualify for zero-tariff treatment. (public-inspection.federalregister.gov)